Overview

Update
Status
Acquired by on July 31, 2013
Total Equity Funding
$15.25M in 3 Rounds from 9 Investors
Headquarters:
Malvern, Pennsylvania
Description:
Ceptaris Therapeutics is a pharmaceutical company developing therapeutics for symptoms of early-stage mycosis fungoides.
Categories:
Therapeutics, Biotechnology, Medical
Website:
http://www.ceptaris.com

Company Details

Update
Founded:
2002
Aliases:
Yaupon Therapeutics
Contact:
610-975-9290
Employees:
11 - 50 | 9 in Crunchbase

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Funding Rounds (4) - $30.25M

Update
DateAmount / RoundValuationLead InvestorInvestors
Jun, 2012$10M / Series D7
Feb, 2012$15M / Debt Financing2
Nov, 2006$4.5M / Series B4
Jun, 2002$750k / Series A0

Current Team (9)

Update

Board Members and Advisors (3)

Update

Offices/Locations (1)

Update
  • Office

    101 Lindenwood Drive

    Suite 400

    Malvern, Pennsylvania 19355

    United States

Images (2)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos